ProShare Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

ProShare Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18,611	Closed	-$445K	–	2453
2021 Q1	$445K	Buy	18,611 +3,183	+21%	+$59.2K	﹤0.01%	1525
2020 Q4	$225K	Buy	+15,428	New	+$204K	﹤0.01%	1790
2014 Q4	–	Sell	-16,532	Closed	-$148K	–	2186
2014 Q3	$148K	Sell	16,532 -3,746	-18%	-$40.3K	﹤0.01%	2079
2014 Q2	$274K	Sell	20,278 -16,024	-44%	-$167K	﹤0.01%	1968
2014 Q1	$361K	Buy	+36,302	New	+$451K	﹤0.01%	2117
2013 Q4	–	Sell	-22,644	Closed	-$275K	–	2045
2013 Q3	$275K	Buy	+22,644	New	+$243K	0.01%	1956

ProShare Advisors's GNMK Position: Q2 2021 in Review

ProShare Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 18,611 shares — an estimated $445K sold.

ProShare Advisors first reported a position in GNMK in Q3 2013 and held it in 6 quarters. The position peaked at $445K in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

ProShare Advisors reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
ProShare Advisors sold 18,611 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $445K.
ProShare Advisors first reported a position in GenMark Diagnostics, Inc in Q3 2013 and held it in 6 quarters.
ProShare Advisors's GenMark Diagnostics, Inc position peaked at $445K in Q1 2021.
0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.